<DOC>
	<DOC>NCT01353794</DOC>
	<brief_summary>The objective of this Non-Interventional study is to evaluate the effectiveness &amp; safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age &gt;70 years) and younger patients (age &lt;70 years). Specifically investigated are the tumor status, duration of Nexavar Â® treatment (number of cycles) and incidence of Hand foot Skin Reaction.</brief_summary>
	<brief_title>Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Sorafenib Exclusion criteria must be read in conjunction with the local product information.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>SORAFENIB</keyword>
	<keyword>RENAL CELL CARCINOMA</keyword>
	<keyword>TYROSINE KINASE INHIBITOR</keyword>
	<keyword>OBSERVATIONAL STUDY</keyword>
</DOC>